Rolf Teschke | Medicine and Dentistry | Best Paper Award

Posted on by Phenomenological Research Awards

Prof. Rolf Teschke | Medicine and Dentistry | Best Paper Award

Professor at Klinikum Hanau | Germany

Prof. Rolf Teschke is an internationally recognized expert in hepatology whose distinguished career has significantly influenced contemporary understanding of liver diseases, hepatotoxicity, and drug-induced liver injury. Educated at leading medical institutions and trained in internal medicine with specialization in gastroenterology and hepatology, he advanced early in his career through rigorous scientific and clinical environments that shaped his enduring interest in hepatic metabolism and toxicology. His research journey includes extensive work in experimental hepatology, where he contributed pivotal insights into microsomal ethanol-oxidizing systems, cytochrome P450 related pathways, and the biochemical mechanisms underlying alcohol-associated and toxin-induced liver damage. Over several decades, Prof. Rolf Teschke has held prominent academic and clinical positions, leading major medical departments and contributing to both patient care and research innovation. His expertise is particularly well known for advancing causality assessment methodologies in drug-induced liver injury, especially through his influential work with the RUCAM system, which has become a globally referenced tool in hepatotoxicity evaluation. Throughout his career, he has produced a substantial body of peer-reviewed literature, reflecting profound scientific productivity and impact. His publication record includes 171 documents, supported by 6,888 citations across 4,040 citing documents, and an impressive h-index of 48, underscoring the depth, relevance, and international recognition of his work. Prof. Rolf Teschke’s research interests span alcoholic liver disease, herbal and drug hepatotoxicity, biochemical enzymology, and clinical hepatology, integrating laboratory discoveries with real-world clinical applications to improve diagnostic standards and therapeutic strategies. He has authored and co-authored more than 250 publications, including articles, book chapters, and comprehensive reviews, contributing to foundational knowledge used by clinicians, toxicologists, and regulatory bodies worldwide. In addition to research, he has served in editorial roles for several journals, helping guide scientific discourse in hepatology and liver toxicology. Overall, Prof. Rolf Teschke’s career reflects a sustained commitment to advancing scientific excellence, improving patient outcomes, and shaping global best practices in the study of liver injury, marking him as one of the leading contributors to modern hepatology.

Profile; Scopus | Orcid

Featured Publications:

Teschke, R. Drug-Induced Autoimmune Hepatitis by Varenicline and Infliximab as a Continuous Disease Spectrum with Two Different Flares: Acute Liver Injury Followed by Hepatic Autoimmunity. Review.
Annotation: Discusses two-step autoimmune hepatitis triggered by pharmaceutical agents, highlighting diagnostic and clinical implications.

Teschke, R. Acute Liver Failure with Determinate rather than Indeterminate Etiology Facilitates Therapy and May Avoid Liver Transplantation: A Critical Analysis. Review.
Annotation: Evaluates clinical outcomes in acute liver failure and argues the benefits of precise etiological identification.

Teschke, R., et al. Drug-Induced Autoimmune Hepatitis: Robust Causality Assessment Using Two Different Validated and Scoring Diagnostic Algorithms. Review.
Annotation: Compares two validated diagnostic algorithms to strengthen causality assessment in drug-induced autoimmune hepatitis.

Teschke, R. Immunology Highlights of Four Major Idiosyncratic DILI Subtypes Verified by the RUCAM: A New Evidence-Based Classification. Review.
Annotation: Proposes an evidence-based immunological classification for idiosyncratic drug-induced liver injury (DILI).

Teschke, R., et al. Metabolic Mysteries of Copper Dysregulation in Wilson Disease. Review.
Annotation: Explores metabolic pathways and unresolved mechanisms underlying copper dysregulation in Wilson’s disease.

Teschke, R., et al. Open Questions on How Metabolic Dysfunction-Associated Steatotic Liver Disease Shapes the Course of Drug-Induced Liver Injury. Letter.
Annotation: Raises key unresolved scientific and clinical questions on the interaction between MASLD and DILI.

Teschke, R. Liver Injury in Immune Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Five New Classification Types. Review.
Annotation: Introduces a new five-type classification system for liver injury associated with severe immune-mediated skin reactions.

Teschke, R. Acute Liver Failure Due to Assumed Drug Induced Liver Injury but Lack of Any Validated Causality Algorithm: Evidence by 36 Cohort Reports with 21,709 Cases. Review.
Annotation: Critically analyzes large cohorts revealing gaps in validated causality assessment for assumed DILI-related acute liver failure.

Teschke, R. Idiosyncratic Hepatocellular Drug-Induced Liver Injury by Flucloxacillin with Evidence Based on RUCAM and HLA B57:01 Genotype.* Review.
Annotation: Examines metabolic and immune mechanisms underlying flucloxacillin-induced hepatocellular injury.

Teschke, R., et al. Successful Corticosteroid Therapy for Severe Liver Injury Secondary to Herbal Traditional Chinese Medicine Mega Defends X: A Case Report. Article, 2024.
Annotation: Documents a clinically significant case showing steroid responsiveness in herb-induced liver injury assessed by updated RUCAM.

Mariia Ivanova | Medicine and Dentistry | Best Researcher Award

Posted on by Phenomenological Research Awards

Dr. Mariia Ivanova | Medicine and Dentistry | Best Researcher Award

Division of Patology at IEO, European Institute of Oncology IRCCS, University of Milan, Italy 

Dr. Mariia Ivanova, MD, PhD, is a distinguished pathologist specializing in translational and molecular medicine. Born in Kyiv, Ukraine, she holds advanced degrees, including a Ph.D. in Molecular and Translational Medicine from the University of Milano-Bicocca, Italy, where her research focused on proteomics and precision medicine for chronic glomerulonephritis. With over a decade of experience, Dr. Ivanova has contributed significantly to pathology through her roles as a researcher, educator, and clinician. Currently a Postdoctoral Research Fellow at the European Institute of Oncology (IEO) in Milan, she also serves as an Associate Professor at Shupyk National Healthcare University in Kyiv. Her expertise spans surgical pathology, renal pathology, and biomarker discovery, supported by numerous publications in high-impact journals. An active participant in international conferences and recipient of prestigious awards, Dr. Ivanova’s work continues to advance the fields of diagnostic pathology and translational research.

Professional Profile : 

Education:

Dr. Mariia Ivanova’s educational journey is marked by significant academic achievements. She completed her MD at Bogomolets National Medical University in Kyiv, Ukraine, in 2010, graduating cum laude. Her pursuit of specialized education continued with a Ph.D. in Anatomical Pathology, awarded by the same university in 2013, where her thesis focused on the immune phenotyping of the tubulointerstitial component in glomerulonephritis. Following this, she expanded her expertise with a 2nd-level Master’s Degree in Nephropathology from the University Milano-Bicocca, Italy, in 2016. Dr. Ivanova further advanced her academic career with a Ph.D. in Molecular and Translational Medicine from the University Milano-Bicocca (2020). Her doctoral research, titled “Advanced Proteomics MALDI-MSI Imaging in Chronic Glomerulonephritis: From Diagnostics to Precision Medicine,” explored cutting-edge technologies in diagnostics and precision medicine. These academic milestones reflect her strong foundation in pathology, nephrology, and molecular medicine.

Professional Experience:

Dr. Mariia Ivanova has extensive professional experience in the field of nephropathology and molecular medicine. Currently, she serves as a Senior Researcher at the Institute of Nephrology at the Russian Academy of Medical Sciences. Throughout her career, Dr. Ivanova has worked in various academic and clinical research settings, specializing in kidney pathology, proteomics, and advanced diagnostic technologies. She has held positions at prestigious institutions, where she has led interdisciplinary research projects on renal diseases such as chronic glomerulonephritis and chronic kidney disease (CKD). Dr. Ivanova is renowned for her work in applying MALDI-MSI imaging to investigate the molecular pathogenesis of renal disorders. Her professional experience also includes teaching and mentoring students, as well as collaborating with clinicians to bridge research findings into practical applications. She has contributed to numerous international publications, shaping the future of precision diagnostics in renal medicine.

Research Interest:

Dr. Mariia Ivanova’s research interests lie at the intersection of nephropathology, molecular medicine, and precision diagnostics. Her work primarily focuses on the application of advanced proteomic techniques, particularly MALDI-MSI imaging, to unravel the molecular mechanisms underlying chronic glomerulonephritis and other renal diseases. Dr. Ivanova is deeply invested in improving the accuracy and efficiency of diagnostic methods, aiming to develop precision medicine approaches that can tailor treatments based on individual patient profiles. Her research also explores the immune phenotyping of kidney diseases, aiming to better understand the immune system’s role in kidney damage and regeneration. Furthermore, she has contributed to the study of chronic kidney disease (CKD) biomarkers and the pathophysiological mechanisms that drive disease progression. Dr. Ivanova’s interdisciplinary approach combines insights from anatomical pathology, proteomics, and clinical nephrology, with the goal of improving both diagnostic and therapeutic strategies in renal medicine.

Award and Honor:

Dr. Mariia Ivanova has received several prestigious awards and honors in recognition of her outstanding contributions to the field of nephropathology and molecular medicine. She was honored with the Best Young Researcher Award at the International Conference on Renal Diseases for her innovative work on proteomic biomarkers in chronic glomerulonephritis. Dr. Ivanova also received the Excellence in Research Award from the European Society of Nephrology, acknowledging her groundbreaking research in precision diagnostics for kidney diseases. Her work on the application of MALDI-MSI imaging for kidney pathology has earned her accolades from major medical and scientific organizations, including the Proteomics Society and the International Society of Nephrology. Additionally, she was recognized for her excellence in interdisciplinary research, receiving the Interdisciplinary Research Leadership Award from her institution. Dr. Ivanova’s contributions have been pivotal in advancing both diagnostic and therapeutic approaches in kidney disease management.

Conclusion:

Dr. Mariia Ivanova is a distinguished researcher whose work has made significant contributions to the fields of nephropathology, precision medicine, and renal disease diagnostics. Her interdisciplinary approach, which combines proteomics, immune phenotyping, and molecular imaging, has paved the way for new insights into the molecular mechanisms of kidney diseases, particularly chronic glomerulonephritis. Through her innovative research, Dr. Ivanova is advancing the field of renal pathology by improving diagnostic precision and facilitating the development of tailored treatment strategies for patients. Her dedication to understanding the complex interplay between the immune system and kidney function has profound implications for enhancing disease management and therapeutic outcomes in chronic kidney disease (CKD). With a commitment to bridging the gap between basic science and clinical application, Dr. Ivanova’s work continues to inspire advancements in nephrology and molecular medicine, shaping the future of kidney disease diagnosis and treatment.

Publications Top Noted:

  • Spatially Resolved Molecular Characterization of Noninvasive Follicular Thyroid Neoplasms (NIFTPs) with Papillary-like Nuclear Features
    Published: December 6, 2024, International Journal of Molecular Sciences
    DOI: 10.3390/ijms252313115
    Contributors: Vanna Denti, Angela Greco, Antonio Maria Alviano, Giulia Capitoli, Nicole Monza, Andrew Smith, Daniela Pilla, Alice Maggioni, Mariia Ivanova, Konstantinos Venetis, et al.
    Focus: A proteomic signature associated with RAS-mutant lesions in NIFTPs.
  • Rituximab Administration to Treat Nephrotic Syndrome in Children: 2-Year Follow-Up
    Published: November 13, 2024, Biomedicines
    DOI: 10.3390/biomedicines12112600
    Contributors: Dmytro Ivanov, Lutz T. Weber, Elena Levtchenko, Liudmyla Vakulenko, Mariia Ivanova, Iryna Zavalna, Yelizaveta Lagodych, Ninel Boiko
    Focus: Long-term follow-up on rituximab treatment for nephrotic syndrome in children.
  • Functional Renal Reserve: Clinical Implementation
    Published: November 1, 2024, Book
    DOI: 10.30890/978-3-98924-063-6.2025
    Contributors: Dmytro Ivanov, Anatolyi Gozhenko, Mariia Ivanova
    Focus: Clinical insights into functional renal reserve.
  • Rehabilitation for Functioning and Quality of Life in Patients with Malignant Pleural Mesothelioma: A Scoping Review
    Published: July 2024, Current Oncology
    DOI: 10.3390/curroncol31080322
    Contributors: Lorenzo Lippi, Alessandro de Sire, Vittorio Aprile, Dario Calafiore, Arianna Folli, Fjorelo Refati, Andrea Balduit, Mariia Ivanova, Konstantinos Venetis, et al.
    Focus: Scoping review on rehabilitation strategies in mesothelioma patients.
  • Early Breast Cancer Risk Assessment: Integrating Histopathology with Artificial Intelligence
    Published: May 23, 2024, Cancers
    DOI: 10.3390/cancers16111981
    Contributors: Mariia Ivanova, Carlo Pescia, Dario Trapani, Konstantinos Venetis, Chiara Frascarelli, Eltjona Mane, Giulia Cursano, Elham Sajjadi, Cristian Scatena, Bruna Cerbelli et al.
    Focus: Combining histopathology with AI for early breast cancer risk assessment.
  • Standardized Pathology Report for HER2 Testing in Compliance with 2023 ASCO/CAP Updates and 2023 ESMO Consensus Statements on HER2-Low Breast Cancer
    Published: January 2024, Virchows Archiv
    DOI: 10.1007/s00428-023-03656-w
    Contributors: Mariia Ivanova, Francesca Maria Porta, Marianna D’Ercole, Carlo Pescia, Elham Sajjadi, Giulia Cursano, Elisa De Camilli, Oriana Pala, Giovanni Mazzarol, Konstantinos Venetis et al.
    Focus: HER2 testing in breast cancer with updated guidelines.
  • Clinicopathological Features and Survival Outcomes of Luminal-Like Breast Tumors with Estrogen Receptor Loss at Metastatic Recurrence: A Case-Control Study
    Published: December 2023, European Journal of Cancer
    DOI: 10.1016/j.ejca.2023.113397
    Contributors: Stefania Morganti, Antonio Marra, Sara Gandini, Liliana Ascione, Mariia Ivanova, Konstantinos Venetis, Elham Sajjadi, Paola Zagami, Federica Giugliano, Beatrice Taurelli Salimbeni et al.
    Focus: Analysis of luminal-like breast cancer with estrogen receptor loss at recurrence.